文献速递妇科

并非所有I期和II期子宫内膜癌都相同:早期高危-中危和高危子宫内膜癌各亚组观察或单独阴道近距离放疗后的无复发生存和病因特异性生存

Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2022-10-14

该研究评估了早期高危-中危(HIR)和高危子宫内膜癌(EC)各亚组在观察或单独阴道近距离放疗(VB)后的无复发生存(RFS)和病因特异性生存(CSS)。研究纳入1999至2016年间在Mayo Clinic和Cleveland Clinic接受手术的I期HIR(GOG-249标准)、II期子宫内膜样癌及I/II期非子宫内膜样癌患者,按16个风险因素亚组估计3年RFS和CSS。结论认为,对于I期子宫内膜样HIR EC中3级、LVSI或IB期因素少于2个者,以及无肌层浸润的IA期非子宫内膜样EC,观察或单独VB可能足够。

要点

  • I期子宫内膜样HIR EC中3级、LVSI或IB期因素<2个者,观察或VB后3年CSS>95%(95%CI下限89.8%)。
  • 无肌层浸润的97例IA期非子宫内膜样EC在观察或VB后3年内无EC相关死亡报告。
  • II期EC无论组织学类型如何,结局均较差。

核心结论

  • 对于I期子宫内膜样HIR EC中3级、LVSI或IB期因素<2个者,以及无肌层浸润的IA期非子宫内膜样EC,观察或单独VB可能足够。
  • 将早期HIR和高危EC分层为风险亚组可能减少过度治疗和治疗不足的风险,应在未来研究中考虑。

研究设计与样本

  • 研究纳入1999至2016年间在Mayo Clinic和Cleveland Clinic接受手术的I期HIR(GOG-249标准)和II期子宫内膜样EC,以及I期和II期非子宫内膜样EC患者。
  • 共识别4156例EC,其中I期子宫内膜样HIR 447例(10.8%)、II期子宫内膜样52例(1.3%)、I期非子宫内膜样350例(8.4%)、II期非子宫内膜样17例(0.4%)。
  • 观察或单独VB分别应用于349例(78.1%)、24例(46.2%)、187例(53.4%)和2例(11.8%)患者。
  • 在由风险因素定义的16个亚组中估计观察或单独VB后的3年RFS和CSS。

主要发现

  • I期子宫内膜样HIR EC中3级、LVSI或IB期因素<2个的亚组,观察或VB后3年CSS>95%(95%CI下限89.8%),而≥2个因素的亚组结局较差。
  • 97例无肌层浸润的IA期非子宫内膜样EC在观察或VB后3年内无EC相关死亡报告。
  • II期EC无论组织学类型如何,结局均较差。

临床怎么用

  • 作者认为,对于I期子宫内膜样HIR EC中3级、LVSI或IB期因素<2个者,以及无肌层浸润的IA期非子宫内膜样EC,观察或单独VB可能足够。
  • 作者建议,将早期HIR和高危EC分层为风险亚组应在未来研究中考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate recurrence-free survival (RFS) and cause-specific survival (CSS) after observation or vaginal brachytherapy (VB) alone in all subgroups of early-stage high-intermediate (HIR) and high-risk endometrial cancer (EC). METHODS: We identified patients with stage I HIR (GOG-249 criteria) and stage II endometrioid EC, and stage I and II non-endometrioid EC who underwent surgery at Mayo Clinic and Cleveland Clinic between 1999 and 2016. Three-year RFS and CSS after observation or VB only were estimated in 16 subgroups defined by risk factors. RESULTS: Among 4156 ECs, we identified 447 (10.8%) stage I endometrioid HIR, 52 (1.3%) stage II endometrioid, 350 (8.4%) stage I non-endometrioid, and 17 (0.4%) stage II non-endometrioid ECs; observation or VB alone was applied in 349 (78.1%), 24 (46.2%), 187 (53.4%), and 2 (11.8%) patients, respectively. After observation or VB, stage I HIR endometrioid EC subgroups with <2 factors among grade 3, LVSI, or stage IB had a 3-year CSS >95% (lower 95% confidence intervals limit: 89.8%), whereas subgroups with ≥2 factors had poorer outcomes. No EC-related deaths after 3 years were reported in 97 stage IA non-endometrioid ECs without myometrial invasion. Stage II ECs had poor outcomes regardless of histology. CONCLUSIONS: Observation or VB only may be sufficient in stage I endometrioid HIR ECs with <2 factors among grade 3, LVSI, or IB and in stage IA non-endometrioid ECs without myometrial invasion. Stratification of early-stage HIR and high-risk ECs into risk subgroups potentially alleviates the overtreatment and undertreatment risk and should be considered in future research.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Garzon S, Grassi T, Mariani A, et al. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer. Gynecol Oncol. 2022. PMID: 36244826. doi:10.1016/j.ygyno.2022.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。